FAK kinase activity is elevated in human PDAC14 and FAK inhibitors, either alone or in combination with immunotherapies, can impair tumour growth in mouse models of PDAC.14 22 23 Clinical trials are now testing FAK inhibitors in combination with immune checkpoint inhibitors in patients with advanced pancreatic cancer (ClinicalTrials.gov; NCT02546531, NCT02758587, NCT03727880). Here, PTK2 is linked to familial pancreatic carcinoma.